<DOC>
	<DOCNO>NCT01537861</DOCNO>
	<brief_summary>Based pre-clinical data investigator hypothesize G-CSF treatment patient multiple myeloma generate 'hostile ' bone marrow microenvironment myeloma cell , deprive key support signal render sensitive chemotherapy . The investigator therefore propose initial pilot study 1 ) explore safety combination G-CSF bortezomib- , carfilzomib- , IMID-based treatment regimens patient bortezomib- , carfilzomib- , IMID-refractory myeloma 2 ) generate correlative data subsequent large study look combination .</brief_summary>
	<brief_title>Filgrastim Treating Patients With Bortezomib- , Carfilzomib- , IMID-Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patient must confirm diagnosis multiple myeloma . The patient may stage multiple myeloma . The patient may receive one line prior therapy ( limit number prior line therapy permissible ) . Patient must ≥18 year age Patient must active treatment one following : twiceweekly bortezomib ( Days 1 , 4 , 8 , 11 21day cycle ) without dexamethasone carfilzomib ( Days 1 , 2 , 8 , 9 , 15 , 16 28day cycle ) without dexamethasone IMID without dexamethasone daily Days 1 21 . Patients treat bortezomib carfilzomb may also receive IMID PO cyclophosphamide regimen . Patient must show stable progressive disease current bortezomib , carfilzomib , IMIDcontaining regimen measurable monoclonal protein component serum ( least 0.5 g/dl electrophoresis 0.05 g/dl [ 50mg/dl ] serumfreelightchain ) . Patients initial response current bortezomib , carfilzomib , IMIDcontaining regimen stable ( plateaued ) disease eligible . Patient must ECOG performance status 0 2 Patient must receive concurrent treatment bisphosphonates , one dose occur within 30 day prior first day ( Day 3 ) protocol treatment Patient must acceptable hematologic parameter , define : Absolute neutrophil count &gt; 1000 cells/mm3 Platelets ≥ 50,000 cells/mm3 Hemoglobin ≥ 8 g/dl Patient must adequate liver function , define : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 x upper limit normal Total bilirubin &lt; 2 x upper limit normal Patient must able understand willing sign write informed consent document Patient must receive agent know suspected antimyeloma activity ( bortezomib , carfilzomib , dexamethasone , IMID PO cyclophosphamide , bisphosphonates current regimen ) Patient must actively use myeloid growth factor Patient must prior malignancy , except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , cancer subject diseasefree least 2 year Patient must uncontrolled medical problem diabetes mellitus , coronary artery disease , hypertension , unstable angina , arrhythmia , pulmonary disease , symptomatic heart failure Patient must neuropathy ≥ grade 3 painful neuropathy ≥ grade 2 ( NCI CTCAE v 4.0 ) Patient must know active infection require IV antibiotic , antiviral , antifungal therapy Patient must pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>